FORTE trial: Impact of minimal residual disease on multiple myeloma patients

Bookmark and Share
Published: 7 Dec 2020
Views: 552
Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy

Dr Stefania Oliva speaks to ecancer about the impact of minimal residual disease (MRD) by multiparameter flow cytometry (MFC) and next-generation sequencing (NGS) on outcome: results of newly diagnosed transplant-eligible multiple myeloma (MM) patients enrolled in the forte trial. This study was presented at this year’s ASH conference.

Dr Oliva initially explains what the Forte trial was about and then speaks of the end-points that were measured in this study. She says MRD was evaluated by these two techniques and the best technique between these two was evaluated. She then talks about the key results from this study and how they can impact the future research and treatment of multiple myeloma.

Dr Oliva mentions why calculating MRD is important for prognosis and treatment and in the end other important derivations from the results.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.